Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13153

UPID:
PAK1_HUMAN

ALTERNATIVE NAMES:
Alpha-PAK; p21-activated kinase 1; p65-PAK

ALTERNATIVE UPACC:
Q13153; O75561; Q13567; Q32M53; Q32M54; Q86W79

BACKGROUND:
PAK1, a serine/threonine-protein kinase, is integral to intracellular signaling, affecting apoptosis, mitosis, and cell migration through its interaction with CDC42 and RAC1. It phosphorylates various substrates, including BAD, RAF1, and SNAI1, modulating cell survival, proliferation, and migration.

THERAPEUTIC SIGNIFICANCE:
Given PAK1's association with a specific neurodevelopmental disorder, exploring its function and regulatory mechanisms offers promising avenues for developing targeted therapies for related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.